Livzon Pharmaceutical Group's (HKG:1513, SHE:000513) net profit attributable to shareholders rose 5.5% to 2.06 billion yuan from 1.95 billion yuan a year earlier, according to a Hong Kong Stock Exchange disclosure on Wednesday.
Earnings per share rose 6.7% year on year to 2.24 yuan from 2.10 yuan.
The Chinese pharmaceutical company's operating income fell 5% to 11.8 billion yuan from 12.4 billion yuan in the preceding year, the disclosure said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。